Cary Pfeffer - 12 Nov 2021 Form 4 Insider Report for Jounce Therapeutics, Inc.

Role
Director
Signature
/s/ Cary Pfeffer
Issuer symbol
N/A
Transactions as of
12 Nov 2021
Net transactions value
$0
Form type
4
Filing time
16 Nov 2021, 18:54:18 UTC
Previous filing
17 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Sale $0 0 $0.000000* 0 12 Nov 2021 See Footnote F1, F2, F3
holding JNCE Common Stock 0 12 Nov 2021 See Footnote F4
holding JNCE Common Stock 50,468 12 Nov 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 12, 2021, Third Rock Ventures III, L.P. ("TRV III") sold 1,900,000 shares of Common Stock of the Issuer at an average price per share of $8.38.
F2 After the above transaction, TRV III owned 1,148,780 shares of Common Stock of the Issuer.
F3 The Reporting Person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of TRV III. The Reporting Person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
F4 Third Rock Ventures II, L.P. ("TRV II") directly holds 2,697,829 shares of the Issuer's Common Stock. The Reporting Person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of TRV II. The Reporting Person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.